CG Oncology saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 67 to 72.
This proprietary rating measures market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the last 52 weeks compares to the rest of the market.
History shows that the best stocks tend to have an 80 or higher RS Rating in the early stages of their moves. See if CG Oncology can continue to rebound and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
CG Oncology is not currently offering a proper buying opportunity. See if the stock goes on to build a base that could spark a new run.
The company showed 0% EPS growth in the latest quarterly report, while sales growth came in at 179%. Keep an eye out for the company's next round of numbers on or around Nov. 27.
CG Oncology holds the No. 264 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
